Literature DB >> 20012604

Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3.

Cornelia L Trimble1, Shiwen Peng, Christopher Thoburn, Ferdynand Kos, T C Wu.   

Abstract

Essentially all squamous cervical cancers and their precursor lesions, high grade cervical intraepithelial neoplasia (CIN2/3), are caused by persistent human papillomavirus (HPV) infection. However, not all CIN2/3 lesions progress to cancer. In a brief, observational study window monitoring subjects with CIN2/3 from protocol entry (biopsy diagnosis) to definitive therapy (cervical conization) at week 15, in a cohort of 50 subjects, we found that 26% of CIN2/3 lesions associated with HPV16, the genotype most commonly associated with disease, underwent complete histologic regression. Nonetheless, HPV16-specific T cell responses measured in peripheral blood obtained at the time of study entry and at the time of conization were marginally detectable directly ex vivo, and did not correlate with lesion regression. This finding suggests that, in the setting of natural infection, immune responses which are involved in elimination of cervical dysplastic epithelium are not represented to any great extent in the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012604      PMCID: PMC2913444          DOI: 10.1007/s00262-009-0806-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  10 in total

1.  Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18.

Authors:  J B Hudson; M A Bedell; D J McCance; L A Laiminis
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype.

Authors:  Cornelia L Trimble; Steven Piantadosi; Patti Gravitt; Brigitte Ronnett; Ellen Pizer; Andrea Elko; Barbara Wilgus; William Yutzy; Richard Daniel; Keerti Shah; Shiwen Peng; Chienfu Hung; Richard Roden; Tzyy Choou Wu; Drew Pardoll
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

3.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

Authors:  Jeffrey R Currier; Ellen G Kuta; Ellen Turk; Lyndsay B Earhart; Larry Loomis-Price; Sylvia Janetzki; Guido Ferrari; Deborah L Birx; Josephine H Cox
Journal:  J Immunol Methods       Date:  2002-02-01       Impact factor: 2.303

4.  Association of human papillomavirus types 16 and 18 E6 proteins with p53.

Authors:  B A Werness; A J Levine; P M Howley
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

Review 5.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

Review 6.  Prevention of cancer through immunization: Prospects and challenges for the 21st century.

Authors:  Ian H Frazer; Doug R Lowy; John T Schiller
Journal:  Eur J Immunol       Date:  2007-11       Impact factor: 5.532

7.  Natural history of cervical squamous intraepithelial lesions: a meta-analysis.

Authors:  J Melnikow; J Nuovo; A R Willan; B K Chan; L P Howell
Journal:  Obstet Gynecol       Date:  1998-10       Impact factor: 7.661

8.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

9.  Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays.

Authors:  Patti E Gravitt; Cheri Peyton; Cosette Wheeler; Raymond Apple; Russell Higuchi; Keerti V Shah
Journal:  J Virol Methods       Date:  2003-09       Impact factor: 2.014

10.  Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia.

Authors:  Nicolas F Schlecht; Robert W Platt; Eliane Duarte-Franco; Maria C Costa; João P Sobrinho; José C M Prado; Alex Ferenczy; Thomas E Rohan; Luisa L Villa; Eduardo L Franco
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

  10 in total
  18 in total

1.  Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.

Authors:  Cornelia L Trimble; Rachael A Clark; Christopher Thoburn; Nicole C Hanson; Jodie Tassello; Denise Frosina; Ferdynand Kos; Jessica Teague; Ying Jiang; Nicole C Barat; Achim A Jungbluth
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

2.  CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.

Authors:  Kevin H Kim; William W Greenfield; Martin J Cannon; Hannah N Coleman; Horace J Spencer; Mayumi Nakagawa
Journal:  Cancer Immunol Immunother       Date:  2011-08-13       Impact factor: 6.968

3.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

Review 4.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

5.  A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

Authors:  Ronald D Alvarez; Warner K Huh; Sejong Bae; Lawrence S Lamb; Michael G Conner; Jean Boyer; Chenguang Wang; Chien-Fu Hung; Elizabeth Sauter; Mihaela Paradis; Emily A Adams; Shirley Hester; Bradford E Jackson; T C Wu; Cornelia L Trimble
Journal:  Gynecol Oncol       Date:  2015-11-23       Impact factor: 5.482

6.  Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.

Authors:  Ruey-Shyang Soong; Liwen Song; Janson Trieu; Jayne Knoff; Liangmei He; Ya-Chea Tsai; Warner Huh; Yung-Nien Chang; Wen-Fang Cheng; Richard B S Roden; T-C Wu; Cornelia L Trimble; Chien-Fu Hung
Journal:  Clin Cancer Res       Date:  2014-06-03       Impact factor: 12.531

7.  Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.

Authors:  Leonel Maldonado; Jessica E Teague; Matthew P Morrow; Iveta Jotova; T C Wu; Chenguang Wang; Cindy Desmarais; Jean D Boyer; Benjamin Tycko; Harlan S Robins; Rachael A Clark; Cornelia L Trimble
Journal:  Sci Transl Med       Date:  2014-01-29       Impact factor: 17.956

Review 8.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Authors:  Joseph G Skeate; Andrew W Woodham; Mark H Einstein; Diane M Da Silva; W Martin Kast
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

9.  Intramuscular vaccination targeting mucosal tumor draining lymph node enhances integrins-mediated CD8+ T cell infiltration to control mucosal tumor growth.

Authors:  Jin Qiu; Shiwen Peng; Andrew Yang; Ying Ma; Liping Han; Max A Cheng; Emily Farmer; Chien-Fu Hung; T-C Wu
Journal:  Oncoimmunology       Date:  2018-05-24       Impact factor: 8.110

10.  Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach.

Authors:  Kei Kawana; Katsuyuki Adachi; Satoko Kojima; Shiro Kozuma; Tomoyuki Fujii
Journal:  Open Virol J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.